Janitor
Home
Ctrl K
LoginRegister

janitor - Build, share, and explore!

•careers•news•status•guidelines•safety•terms•privacy policy•support
v

@valued_at_up_to_and_the_money

0 followers
Member Since Oct 12, 2026

Valued At, Up To, and the Money That Actually Changes Hands

Two short phrases carry the biggest numbers in business news about private companies: "valued at" in funding announcements and "up to" in acquisition announcements. Both point to real figures, but each sits closer to a ceiling than to a price, describing the most favorable reading of a deal rather than what an ordinary shareholder owns or what a buyer will actually pay. Funding rounds and acquisitions are among the most common announcements a young company makes, whether they are drafted in-house or with an agency such as techwavespr.com, and the figure in the first line is the one that ends up in headlines, investor updates and job offers. A peer-reviewed study of 135 unicorns, data on private-company acquisitions and two court fights over billions in contingent payments show how far that figure can sit from the money, and which questions close the gap.

What a Funding Valuation Actually Measures

When a startup announces that it raised $100 million at a $1 billion valuation, the billion usually comes from one multiplication: the price per share the new investors paid, times every share the company has issued or promised, including founders' common stock and the pool set aside for employee options. The new investors did not buy common stock, though. They bought preferred shares, which typically let them recover their money ahead of common shareholders when the company is sold, and which sometimes add guarantees, vetoes or seniority over earlier investors. The calculation treats every share in the company as if it were worth as much as the newest and best-protected one.

A simplified case shows why that matters. Suppose the new investors paid $100 million for 10% of the company with a standard 1x non-participating liquidation preference, and the company is later sold for $300 million. Converting to common would give them 10% of the proceeds, or $30 million, so they take their $100 million preference instead, and the holders of the other 90% split the remaining $200 million. The announcement valued the company at a billion. The sale hands the holders of 90% of the shares a fifth of that figure.

Employees meet the same gap in their own paperwork. The appraisal that sets the strike price of stock options, known as a 409A valuation, prices common stock separately from preferred. When Seth Levine of Foundry Group compared those appraisals with the price of the last preferred round across his firm's portfolio in 2018, they clustered around 36% of that price regardless of the company's stage.

The Unicorn Gap and Square's Guarantee

Will Gornall of the University of British Columbia and Ilya Strebulaev of Stanford measured the distance between headline and value across the most celebrated private companies. They went through the legal filings of 135 US unicorns, valued each class of shares on its own terms, and found that reported post-money valuations were on average 48% higher than fair value, with 14 companies at more than double their fair value. The protections behind the gap were common: 15% of the companies had given recent investors IPO return guarantees, 24% had given them vetoes over IPOs below a set price, and 30% had placed them ahead of every other investor. Common stock, which carries none of these rights, came out 56% overvalued, and after the adjustment 65 of the 135 no longer cleared $1 billion. The study was published in the Journal of Financial Economics in 2020.

Square's IPO in November 2015 put one of those guarantees on public display. Its Series E investors had paid $15.46 a share in a round that valued the payments company at about $6 billion, and their terms promised additional shares if Square went public below $18.56, a price that would have given them a 20% return. Square priced its offering at $9, which valued the company at about $2.9 billion. The Series E holders received roughly 10.3 million extra shares, worth about $93 million at the offering price, and the dilution fell on everyone else, including earlier investors and employees. Both valuations were accurate when they were reported. The first priced a share that came with a guaranteed return, and the second priced shares that came with none.

How Much of "Up To" Ever Gets Paid

Acquisitions have their own version of the problem. When part of the price is paid at closing and the rest depends on the acquired business hitting targets afterwards, a structure known as an earnout, the announcement can present the total as a deal worth "up to" the combined figure. These structures are spreading. SRS Acquiom, which acts as shareholder representative and paying agent in private-company deals, found earnouts in 24% of the private-target deals it tracked in 2025 outside life sciences, compared with a historical norm closer to 15%, and in more than three quarters of biotech and pharma deals. The contingent share is largest in small transactions: among 2025 deals with an earnout, an analysis by Rahul Chhabra of Charles River Associates put the median at 39.2% of deal value below $10 million and about 20% above $500 million.

The payout record is thinner than the headlines. In SRS Acquiom's data, sellers in deals where the earnout paid anything received about 50 cents per potential dollar, and across all deals with earnouts the figure falls to roughly one dollar in five. Size matters here too: lower-middle-market deals with some payout had a median of 43 cents on the dollar, against 67 cents for deals with more than $50 million paid upfront.

Johnson & Johnson's purchase of the surgical robotics company Auris Health shows how contingent money can end up in court. The February 2019 announcement listed about $3.4 billion in cash plus up to $2.35 billion in milestone payments. In the first quarter of 2020, J&J recorded roughly $1 billion of income from reversing part of that contingent liability, explaining in a filing that certain milestones were no longer expected to be met on its current timelines. None of the milestones was ever reached. The former shareholders' representative sued, and in 2024 the Delaware Court of Chancery awarded more than $1 billion in damages. In January 2026 the Delaware Supreme Court reversed the part of the award tied to the first milestone, about $300 million, but upheld the rest, including a finding that J&J had fraudulently induced Auris to accept a contingent payment instead of more cash upfront for one milestone. The court also held that weighing earnout savings in strategic decisions was the kind of "earnout-avoiding decision making" the contract prohibited.

Five Weeks and $6.4 Billion

Public-company deals use a close relative of the earnout, the contingent value right, or CVR, which gives target shareholders a contractual claim on future milestones. When Bristol Myers Squibb bought Celgene in 2019, each Celgene share came with a CVR worth $9 in cash if three drugs won FDA approval on time, two of them by December 31, 2020, and the third by March 31, 2021. Two did. The lymphoma therapy liso-cel, now sold as Breyanzi, was approved on February 5, 2021, 36 days after its deadline, and the CVRs, worth about $6.4 billion in total, paid nothing.

UMB Bank, acting as trustee for the holders, sued in 2021, arguing that Bristol Myers had not used the diligent efforts the agreement required. A federal judge dismissed the case in 2024 because the trustee had not been appointed by the registered holders as the agreement specified, and in August 2026 the Second Circuit revived it, finding that all parties to the agreement, Bristol Myers included, had accepted UMB as trustee. Whatever the courts conclude on the merits, the structure is the lesson. Once a deal closes, the buyer controls the budgets, regulatory filings and timelines that decide whether contingent money is paid, while the sellers hold a contract and, if it comes to that, a lawsuit.

Questions to Ask Before Repeating the Number

None of this makes the headline figure false. It makes it incomplete, and five questions recover most of what is missing:

  1. Which shares set the price? A post-money valuation multiplies the newest investors' price per share across the whole company, so ask what those shares carry: liquidation preference, seniority, IPO protection or participation rights.

  2. What is the common stock worth? For anyone holding options, the latest 409A value per share, set against the preferred price, shows how much of the headline actually applies to them.

  3. How much changes hands at closing? Separate the upfront payment from contingent amounts, and treat the contingent part as an uncertain claim rather than money owed.

  4. Who controls the milestones? Payments that depend on the buyer's budgets, sales effort or regulatory filings rest on the efforts clause in the contract and, in a dispute, on the seller representative or trustee who has to enforce it.

  5. Does the contingent part have a market price? Some CVRs are listed and trade, and their price is an independent estimate of what investors think the promise is worth.

The figure in the first line of an announcement is written for a single news cycle, while the share terms and milestone clauses behind it decide who gets paid for years. Reading both is how founders, employees and investors avoid confusing a ceiling with a price, and that second reading is what this podcast is about.

No characters